Product/Composition:- | Ibrutinib |
---|---|
Strength:- | Capsule:140 mg, 70 mg; Tablet: 140 mg |
Form:- | Capsules and tablets |
Reference Brands:- | Imbruvica®(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used to treat B-cell malignancies like CLL, MCL, and Waldenström's macroglobulinemia. It works by blocking Bruton’s tyrosine kinase to prevent cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a crucial B2B oncology product for healthcare providers.
Ibrutinib (brand name Imbruvica®) is a BTK inhibitor used in oncology and hematology to treat B-cell malignancies like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and Waldenström's macroglobulinemia. By blocking Bruton’s tyrosine kinase (BTK), Ibrutinib disrupts B-cell signaling, preventing cancerous B-cell growth. Available in oral capsules (70 mg, 140 mg) and oral tablets (140 mg), it is approved for use in both the US and EU. Marketed by AbbVie and Janssen Pharmaceuticals, Imbruvica® is a key product for B2B pharmaceutical transactions in the oncology and hematology sectors.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications